Postoperative Dose of Parathyroid Hormone as a Marker for the Occurrence of Hypoparathyroidism After Total Thyroidectomy
Diagnostic Value of Immediate Postoperative Dose of Parathyroid Hormone as a Marker for the Occurrence of Hypoparathyroidism After Total Thyroidectomy: A Retrospective Observational Study
1 other identifier
observational
300
0 countries
N/A
Brief Summary
The main objective of this study is to establish an optimal threshold Early parathormon (PTH) assay in order to exclude hypoparathyroidism , that is to say to obtain a negative predictive value of hypoparathyroidism highest possible.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Feb 2012
Longer than P75 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2012
CompletedFirst Submitted
Initial submission to the registry
September 13, 2016
CompletedFirst Posted
Study publicly available on registry
October 5, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2018
CompletedNovember 21, 2025
September 1, 2016
6.9 years
September 13, 2016
November 18, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
the presence/absence of hypoparathyroidism
hypoparathyroidism is defined as: corrected serum calcium Day 1 \<1.90 and / or symptoms of hypocalcemia (cramps, tingling of the extremities and peri-oral) to Day 1 authenticated by a VAS score\> 3.
day 1
Study Arms (1)
Patients with total thiroidectomy
Interventions
Eligibility Criteria
Included patients underwent total thyroidectomy from 1 February 2012 to 1 December 2013 at the Nîmes University Hospital
You may qualify if:
- Patients consecutively operated on between February 1, 2012 and December 1, 2013
- Total thyroidectomy +/- lymphadenectomy
- Respect of clinicobiological protocol presented above
- The ( the ) patient ( e) was informed ( e) on the implementation of the study 's objectives, constraints and patient rights
- The ( the ) patient ( e) is under ( e) at least 18 years
You may not qualify if:
- The ( the ) patient ( e) is under guardianship, curatorship or under guard saves justice
- It is not possible to give to ( the ) patient ( e) informed information
- History of cervical radiotherapy
- Previous history of dysfunction of the parathyroid glands
- Previous history of surgery of the parathyroid glands
- A history of kidney failure or hepatocellular
- History of osteomalacia or Paget's disease
- unhealed cancer antecedent
- History of sarcoidosis
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (1)
Galy-Bernadoy C, Lallemant B, Chambon G, Pham HT, Reynaud C, Alovisetti C, Bonduelle Q, Guedj AM, Lumbroso S, De Brauwere DP. Parathyroid Hormone Assays following Total Thyroidectomy: Is There a Predictive Value? Eur Thyroid J. 2018 Jan;7(1):34-38. doi: 10.1159/000484689. Epub 2017 Dec 7.
PMID: 29594052RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 13, 2016
First Posted
October 5, 2016
Study Start
February 1, 2012
Primary Completion
December 31, 2018
Study Completion
December 31, 2018
Last Updated
November 21, 2025
Record last verified: 2016-09